Review

Stem cell-based therapies for neurological disorders

  • Cell-based therapies have been previously performed using fetal tissues for some central nervous system (CNS) disorders, such as Parkinson’s disease. However, it can be difficult to collect a large number of cells for transplantation. Recent studies revealed that some stem cells can act as potential sources of cell-based therapies for degenerative and damaged areas in the CNS. In addition, stem cells can be used as cellular delivery vehicles for brain tumor because of tumor-tropic migratory capacity. Embryonic stem (ES) cells, mesenchymal stem cells (MSCs), and induced pluripotent stem (iPS) cells are the most attractive stem cells. iPS cells can be efficiently differentiated to neural stem cells and have the possibilities to overcome the ethical issues associated with ES cells. Therefore, cell-based therapies using iPS cells can be developed specifically for neurological disorders. In this article, we review the characteristics of ES cells, MSCs, and iPS cells as cell sources for stem cell-based therapies, and then discuss preclinical data and ongoing clinical trials for the CNS disorders.

    Citation: Ryota Tamura, Masahiro Toda. Stem cell-based therapies for neurological disorders[J]. AIMS Cell and Tissue Engineering, 2018, 2(1): 24-46. doi: 10.3934/celltissue.2018.1.24

    Related Papers:

    [1] Adrian Schmid-Breton . Transboundary flood risk management in the Rhine river basin. AIMS Environmental Science, 2016, 3(4): 871-888. doi: 10.3934/environsci.2016.4.871
    [2] Gene T. Señeris . Nabaoy River Watershed potential impact to flooding using Geographic Information System remote sensing. AIMS Environmental Science, 2022, 9(3): 381-402. doi: 10.3934/environsci.2022024
    [3] Vijendra Kumar, Kul Vaibhav Sharma, Nikunj K. Mangukiya, Deepak Kumar Tiwari, Preeti Vijay Ramkar, Upaka Rathnayake . Machine learning applications in flood forecasting and predictions, challenges, and way-out in the perspective of changing environment. AIMS Environmental Science, 2025, 12(1): 72-105. doi: 10.3934/environsci.2025004
    [4] G Mathias Kondolf, Pilar Lopez-Llompart . National-local land-use conflicts in floodways of the Mississippi River system. AIMS Environmental Science, 2018, 5(1): 47-63. doi: 10.3934/environsci.2018.1.47
    [5] Ronak P. Chaudhari, Shantanu R. Thorat, Darshan J. Mehta, Sahita I. Waikhom, Vipinkumar G. Yadav, Vijendra Kumar . Comparison of soft-computing techniques: Data-driven models for flood forecasting. AIMS Environmental Science, 2024, 11(5): 741-758. doi: 10.3934/environsci.2024037
    [6] Said Qasim, Mohammad Qasim, Rajendra Prasad Shrestha, Amir Nawaz Khan . An assessment of flood vulnerability in Khyber Pukhtunkhwa province of Pakistan. AIMS Environmental Science, 2017, 4(2): 206-216. doi: 10.3934/environsci.2017.2.206
    [7] RAHMOUN Ibrahim, BENMAMAR Saâdia, RABEHI Mohamed . Comparison between different Intensities of Rainfall to identify overflow points in a combined sewer system using Storm Water Management Model. AIMS Environmental Science, 2022, 9(5): 573-592. doi: 10.3934/environsci.2022034
    [8] Ignazio Mongelli, Michalis Vousdoukas, Luc Feyen, Antonio Soria, Juan-Carlos Ciscar . Long-term economic impacts of coastal floods in Europe: a probabilistic analysis. AIMS Environmental Science, 2023, 10(5): 593-608. doi: 10.3934/environsci.2023033
    [9] Finu Shrestha, Kabir Uddin, Sudan Bikash Maharjan, Samjwal Ratna Bajracharya . Application of remote sensing and GIS in environmental monitoring in the Hindu Kush Himalayan region. AIMS Environmental Science, 2016, 3(4): 646-662. doi: 10.3934/environsci.2016.4.646
    [10] Kitipol Nualtong, Ronnason Chinram, Piyawan Khwanmuang, Sukrit Kirtsaeng, Thammarat Panityakul . An efficiency dynamic seasonal regression forecasting technique for high variation of water level in Yom River Basin of Thailand. AIMS Environmental Science, 2021, 8(4): 283-303. doi: 10.3934/environsci.2021019
  • Cell-based therapies have been previously performed using fetal tissues for some central nervous system (CNS) disorders, such as Parkinson’s disease. However, it can be difficult to collect a large number of cells for transplantation. Recent studies revealed that some stem cells can act as potential sources of cell-based therapies for degenerative and damaged areas in the CNS. In addition, stem cells can be used as cellular delivery vehicles for brain tumor because of tumor-tropic migratory capacity. Embryonic stem (ES) cells, mesenchymal stem cells (MSCs), and induced pluripotent stem (iPS) cells are the most attractive stem cells. iPS cells can be efficiently differentiated to neural stem cells and have the possibilities to overcome the ethical issues associated with ES cells. Therefore, cell-based therapies using iPS cells can be developed specifically for neurological disorders. In this article, we review the characteristics of ES cells, MSCs, and iPS cells as cell sources for stem cell-based therapies, and then discuss preclinical data and ongoing clinical trials for the CNS disorders.


    Genetic regulatory networks, often abbreviated as GRNs, are complex systems that include several components that work together to regulate gene expression. These networks encompass a wide range of interactions, including those between DeoxyriboNucleic Acid (DNA) and proteins (such as transcription factors), RiboNucleic Acid (RNA) and proteins (like ribosomes and RNA-binding proteins), and even interactions among different types of RNA. GRNs play a pivotal role in understanding various biological processes and have garnered significant attention from researchers [1]. Over the last couple of years, advances in molecular-level biology research have highlighted the significance of genetic networks, which are inherently complex and need simplification. GRNs have successfully described biochemical reactions such as gene transcription, translation, and protein diffusion, similar to the achievements in artificial neural network modeling, which have resulted in a plethora of models. Various models have emerged, including the Bayesian model [2], the Boolean model [3,4], and the differential equation model [5,6]. In particular, the differential equation model is good at describing the continuous evolution of a system state over time, and usually can reflect the real dynamics of the system more accurately. However, continuous systems are not suitable for computer processing, so many studies have converted continuous systems into discrete systems [7,8]. In this context, incorporating delayed discrete-time GRNs becomes crucial for simulation and implementation [9]. Numerous excellent results in [10,11] have analyzed exponential stability, made synchronization control, designed guaranteed cost control, and updated estimation methods for discrete-time GRNs. Recently, some notable contributions have further enriched this field. By resorting to the sliding-mode control, Li et al. [12] effectually extended and modified the existing works on the stabilization problem for delayed uncertain semi-Markovian switching complex-valued networks. They proposed sufficient criteria for stochastic stability based on the generalized Dynkin's formula and Lyapunov stability theory. In addition to these works, Narayanan et al. [13] addressed the problem of Mittag-Leffler synchronization of T-S fuzzy fractional-order discrete-time complex-valued molecular models of mRNA and protein in regulatory mechanisms with two kinds of regulation functions. Wei et al. [14] addressed the dissipation synchronization issue of semi-Markovian jumping delayed neural networks under random deception attacks and explained the specific influence of deception attacks on event trigger time for the first time. Pandiselvi et al. [15] studied the approximation concern for the discrete-time stochastic GRNs with the leakage delays, distributed delays, and probabilistic measurement delays into the problem and modeled the robust H state estimator for a class of discrete-time stochastic GRNs. Zhao and Wu [16] contributed to the field by establishing new fixed/prescribed-time stability criteria for stochastic systems with time delay and designed delay-independent control mechanisms that are applicable to systems with unknown delays. These studies highlight the importance of addressing key issues in GRN control and synchronization. The study of discrete-time GRN with spatial coupling has gained significant attention due to its importance in understanding the spatial and temporal dynamics of gene expression. In recent years, discrete-time GRNs with spatial coupling have emerged as a crucial area of research in systems biology as they integrate temporal and spatial dynamics to provide a more comprehensive understanding of gene regulation processes. Unlike existing literature that limits its focus to discrete-time networks, Zhang and Li [17] explored the double effects of both discrete time and discrete spatial diffusions in switching complex dynamical networks. Their work is ground breaking in its consideration of discrete spatial diffusions, offering a robust theoretical and practical foundation for future research in this area. Liang and Wang [18] studied the passivity for coupled reaction-diffusion neural networks with multiple state couplings or spatial diffusion couplings by employing the proportional-derivative control method. This research provides valuable insights into the control and synchronization of networks with reaction-diffusion terms. Discrete-time GRNs with spatial coupling have also been applied to study gene regulatory networks in disease and aging. Avila et al. [19] delineated different types of GRNs and provided their biological interpretation, highlighting the potential of discrete-time GRNs with spatial coupling to uncover the underlying mechanisms of complex diseases and aging processes.

    Passivity, a mathematical principle describing a system or function's ability to absorb or retain energy under specific conditions, is often linked to energy retention and dissipation in control theory. At its core, passivity delineates a system's capacity to absorb, dissipate, or retain energy without amplifying it under specified conditions, thereby ensuring stability and boundedness in its state space. A dynamic system is deemed passive if its energy does not increase within its state space [20]. Recently, the concept of dissipation has found widespread application in various fields, including chemistry, biology, complex networks, signal processing, chaos control, and social sciences. Consequently, exploring the passivity of gene regulatory networks is crucial due to its relevance in numerous research and analytical spheres.

    In genetic regulation, biochemical reactions involve the diffusion of regulatory proteins and metabolites between the cytosol and nucleus. It is more accurate to consider reaction-diffusion models for genetic regulatory networks than to assume spatial homogeneity. In fact, it has been suggested that reaction-diffusion systems play an important role in the dynamics of GRNs [21,22]. Mathematical models without considering reaction-diffusion effects may lead to incorrect predictions of protein and mRNA concentrations. Therefore, it is essential to consider reaction-diffusion systems in the models of GRNs. However, there are few relevant articles, especially in the study of discrete-time GRNs with reaction-diffusion in plants. In discrete-time gene regulatory networks, the nature of reaction-diffusion reflects the coupling between adjacent spatial locations. Specifically, it represents the interaction between neighboring spatial locations due to their close proximity, which leads to mutual influence on each other's function. Based on this observation, the present study establishes a gene regulatory network model that incorporates the mutual coupling between spatial locations. The GRNs constructed through differential equations in [5,6] are continuous models that solely reflect the temporal changes in protein and mRNA concentrations. In contrast to the continuous models proposed in [5,6], the proposed discretized GRN model offers additional insights. It can not only capture temporal variations in protein and mRNA concentrations but also reveal their spatial variations through the inclusion of reaction-diffusion terms. Computer simulations demonstrate the effectiveness of the theoretical results and the importance of incorporating reaction-diffusion terms in GRN models.

    The main difficulties and challenges of this paper stem from the fact that the diffusion terms in GRNs first appeared in models described by differential equations, with limited research on discrete-time GRNs. For electronic computers, continuous models are not directly describable. Therefore, the modeling of continuous GRNs becomes highly necessary. However, since spatial diffusion is characterized by the spatial divergence of mRNA and protein concentrations, defining the spatial diffusion terms of mRNA and proteins in discrete-time GRN models and proving that such models exhibit passivity is quite challenging. In this paper, we address these challenges by discretizing spatial divergence and leveraging Lyapunov functions and linear matrix inequalities to provide solutions.

    The main contributions of this article are as follows:

    1) The introduction of the concept of spatial diffusion into a discrete GRN, constructing a discretely coupled gene regulatory network with reaction diffusion.

    2) By considering Brownian motion and time delay, the article provides a theorem for determining the passivity in a discretely GRN with Dirichlet boundary conditions and reaction diffusion.

    For readability, the meanings of commonly used mathematical symbols involved in this paper are as follows:

    RN means the N dimensional real vector, and RN×N stands for the sets of N×N real matrices. f(x)x denotes the partial derivative of f(x) with respect to x. Ni=1γi=γ1+γ2++γN, Ni=1αi={α1,α2,αN}. The superscript T stands for matrix transposition.

    A typical nonlinear delayed genetic regulatory network based on a differential equation model with reaction-diffusion terms is described as [21]:

    {m(t,x)t=lk=1xk(Mkm(t,x)xk)Am(t,x)+Bf(p(tt(k),x))+u(t,x)p(t,x)=lk=1xk(Mkm(t,x)xk)Cp(t,x)+Dm(tδ(t),x)+v(t,x) (2.1)

    where

    A=diag{a1,a2,,aN},
    C=diag{c1,c2,,cN},
    D=diag{d1,d2,,dN},
    m(t,x)=[m1(t,x),m2(t,x),,mN(t,x)]T,
    p(t,x)=[p1(t,x),p2(t,x),,pN(t,x)]T,
    u(t,x)=[u1(t,x),u2(t,x),,uN(t,x)]T,
    v(t,x)=[v1(t,x),v2(t,x),,vN(t,x)]T,
    f(p(tτ(t),x))=[f1(p1(tτ(t),x)),,fN(pN(tτ(t),x))]T,

    and B=(bnn)RN×N, bnn represents the interaction between transcription factors and genes. Specifically, bnn can take one of three values: αnn, 0, or αnn. Here, αnn represents the magnitude of the interaction occurring between transcription factor n and gene n. In detail, a positive αnn signifies that there is an activating influence, a zero value indicates the absence of any direct interaction, and a negative αnn signifies that there is a repressing influence.

    In Eq (2.1), the matrix B represents the interactions between genes in the GRN. The notations mn(t,x) and pn(t,x) (n=1,2,,N) represent the concentrations of mRNA and protein at time t for the nth node, respectively. The vector x=(x1,x2,,xl)T belongs to the set Q. Specifically, Q is defined as {x||xα|Lα,α=1,2,,l} and represents a compact set in the real vector space Rl with a smooth boundary Q. The terms u(t,x) and v(t,x) stand for the disturbance input signals. The parameters A and C are the degradation rates of the mRNA and protein, respectively, while D signifies the translation rate. The matrices Mα>0 and Mα>0 demonstrate the diffusion coefficient matrices. The regulatory function fn(x) is in the Hill form and captures the feedback regulation of protein on transcription; its mathematical form is described as

    fn(x)=(xvn)Hn1+(xvn)Hn, (2.2)

    where Hn is the Hill coefficient and vn is a positive constant.

    Based on Eq (2.1), we construct a corresponding discrete gene regulatory network model with reaction diffusion terms, as shown in Figure 1.

    {m(k+1,i)=Am(k,i)+Bf(p(kτ(k),i))+Δ1+u(k,i)p(k+1,i)=Cp(k,i)+Δ2+Dm(kδ(k),i)+v(k,i) (2.3)

    where

    m(k,i)=[m1(k,i),m2(k,i),,mN(k,i)]T,p(k,i)=[p1(k,i),p2(k,i),,pN(k,i)]T,u(k,i)=[u1(k,i),u2(k,i),,uN(k,i)]T,v(t,x)=[v1(k,i),v2(k,i),,vN(k,i)]T,f(p(kτ(k),i))=[f1(p1(kτ(k),i)),,fN(pN(kτ(k),i))]T,

    mn(k,i) and pn(k,i) represent the concentration of mRNA and protein of the nth node at the time kN and space i respectively, where i=1,2,,L. Δ1 and Δ2 represent the reaction diffusion terms of concentrations of mRNA and protein, respectively. The discretization of the spatial diffusion term is obtained by discretizing the spatial diffusion term of the continuous gene regulatory network as shown in Eq (2.3), with the specific correspondence shown in the following equations:

    lk=1xk(Mkm(t,x)xk)=lk=1Mk2m(t,x)x2k. (2.4)
    Figure 1.  GRNs with a reaction-diffusion term and coupling for transcription and translation processes.

    In the modeling of gene regulatory networks, it is very important to choose a suitable discretization scheme. Different discretization schemes may have advantages in different application scenarios. For example, the forward difference and backward difference methods may be easier to implement or more efficient in some cases, although their accuracy is low. In our model, the discretization formula for the second-order partial derivative 2m(t,x)x2k typically employs the central difference method for approximation because this method estimates the derivative of a point by calculating the values on both sides of the functio. This can provide a more accurate derivative approximation and is very important for understanding and predicting the behavior of gene regulatory networks. In addition, the central difference method can better maintain the physical meaning and mathematical properties of the system when dealing with the spatial diffusion term.

    For the function m(t,x), the discretization formula for its second-order partial derivative is as follows:

    2m(t,x)x2km(t,x+hk)m(t,x)(m(t,x)m(t,xhk))h2k, (2.5)

    where hk is the step size in the direction of xk.

    After the model is discretized, the spatial diffusion term also needs to be discretized. The term m(t,x) is transformed into m(t,i), where t corresponds to time, and i corresponds to the spatial position x. The discretization process is carried out to facilitate computer simulation and computation. Clearly, in discrete systems, the step size is typically taken as 1, that is, hk=1, and Eq (2.5) can be simplified as follows:

    m(t,x+hk)m(t,x)(m(t,x)m(t,xhk)). (2.6)

    If Mk is set to θ, then the reaction-diffusion term of mRNA concentration

    Δ1=θ[m(k,i+1)m(k,i)(m(k,i)m(k,i1))] (2.7)

    in the discrete form can be obtained. Similarly, the reaction-diffusion term Δ2 for protein concentration can be obtained in the discrete form, and thus we arrive at Eq (2.8).

    {Δ1=θ[m(k,i+1)m(k,i)(m(k,i)m(k,i1))]Δ2=μ[p(k,i+1)p(k,i)(p(k,i)p(k,i1))] (2.8)

    where θ and μ are positive coupling coefficients.

    Once Eq (2.8) has been substituted into Eq (2.3), and the subsequent simplification process has been carried out, the final expression is obtained:

    {m(k+1,i)=Am(k,i)+Bf(p(kτ(k),i))+θ(m(k,i+1)+m(k,i1))+u(k,i)p(k+1,i)=Cp(k,i)+μ(p(k,i+1)+p(k,i1))+Dm(kδ(k),i)+v(k,i) (2.9)

    where A=A2θ and C=C2μ.

    Remark 2.1. To provide a concrete application example, we refer to the research by Zhang et al. [23], which effectively demonstrates the importance of combining regulatory networks with reaction-diffusion terms. Zhang et al. studied the oscillatory expression of Escherichia coli mediated by microRNA, incorporating both time delays and reaction-diffusion components. They demonstrated that the oscillatory expression of Escherichia coli is not only critically dependent on transcriptional and translational delays but also significantly influenced by the diffusion coefficients. This conclusion has been practically verified by numerous biological experiments and observations. They also found that if the diffusion coefficients of microRNA, mRNA, and protein are sufficiently small, non-uniform periodic oscillations can be predicted to occur, unless only spatially uniform periodic oscillations are exhibited. Thus, the application example provided by Zhang et al. [23] serves as a practical illustration of how the combination of regulatory networks and reaction-diffusion terms, as considered in our paper, can be applied to model and understand complex biological phenomena such as the oscillatory expression of Escherichia coli.

    The current research focuses on the Dirichlet boundary condition, which is characterized by the following mathematical expressions:

    {mn(k,i)=0,iΩpn(k,i)=0,iΩ (2.10)

    Here, the symbol Ω denotes the boundary of the domain under consideration.

    Dirichlet boundary conditions provide a clear and physically meaningful way to define the behavior of the system at the boundaries, which is very important for drawing meaningful conclusions about the passivity and stability of the network. The use of Dirichlet boundary conditions in our model enables us to focus on the internal dynamics of the system instead of being dispersed by the complexities of boundary behavior. This simplification enables us to deduce the analysis results, which provide a deep understanding of the behavior of gene regulatory networks with spatial diffusion. The unique contribution of our research lies in applying these boundary conditions to solve the specific problem of analyzing the passivity of discrete gene regulatory networks with spatial diffusion.

    Considering that the concentrations of mRNA and proteins are influenced by molecular Brownian motion, Eq (2.9) is rewritten as

    {m(k+1,i)=Am(k,i)+Bf(p(kτ(k),i))+θ(m(k,i+1)+m(k,i1))+σ(p(k,i),p(kτ(k),i))ω(k,i)+u(k,i)p(k+1,i)=Cp(k,i)+μ(p(k,i)+p(k,i)+Dm(kδ(k),i))+v(k,i) (2.11)

    where ω(k,i) represents a vector-form scalar Brownian motion with the following properties:

    ε{ω(k,i)}=0,ε{ω(k,i)Tω(k,i)}=1,ε{ω(k,i)Tω(k,i)}=0(kk),

    and σ(p(k,i),p(kτ(k),i)) is the noise intensity matrix satisfying

    σT(pn(k,i),pn(kτ(k),i))σ(pn(k,i),pn(kτ(k),i))pTn(k,i)H1pn(k,i)+pTn(kτ(k),i)H2pn(kτ(k),i) (2.12)

    where H1 and H2 are known constant matrices of appropriate dimensions.

    τ(m) and δ(m) are time-varying delays satisfying

    {0<τminτ(m)τmax0<δminδ(m)δmaxϕ1˙τϕ1ϕ2˙δϕ2 (2.13)

    The nonlinear function fi() satisfies Inequality (2.14) due to its monotonic increasing nature with saturation

    0fi(xi)xiδi,xi0,i=1,2,,n. (2.14)

    Furthermore, this inequality can be reformulated in matrix form as follows:

    fT(x)(f(x)Kx)0, (2.15)

    where K=diag(k1,k2,kn),xRn.

    Lemma 2.2 ([24]). For any constant matrix W=WT>0, scalar r>1, there is

    rk1l=krxT(l)Wx(l)k1l=krxT(l)Wk1l=krx(l). (2.16)

    Lemma 2.3 ([24]). For every pair of vectors X,YRn, where H>0 denotes a positive definite matrix, the subsequent inequality is guaranteed to exist

    2XTHYXTHX+YTH1Y. (2.17)

    The general form of a linear matrix inequality (LMI) is as follows:

    LMI(x)=A0+x1A1+x2A2++xnAn0, (3.1)

    where x=(x1,x2,,xn) is a vector of real decision variables, and A0,A1,,An are given symmetric matrices (typically real-valued). Note that the symbol 0 indicates that the matrix is positive semidefinite, which means all its eigenvalues are non-negative. The solution set of LMI is a convex set, meaning that its solution space has favorable mathematical properties. However, this also limits the range of feasible solutions. This convexity makes LMI very useful in optimization problems, but it increases its constraint. LMI is often used in system stability analysis, such as for verifying the stability of the system through Lyapunov functions. The application environment requires LMI to satisfy strict mathematical conditions to ensure the stability of the system.

    In the subsequent discussions, an exploration will be conducted into a stability criterion pertaining to Eq (2.12) when subjected to Dirichlet boundary conditions.

    Theorem 3.1 ([24]). For given scalars δ and τ satisfying Inequality (2.13), and under the condition ω(k,i)=0, the trivial solution of Eq (2.12) without molecular Brownian motion under Dirichlet boundary conditions is passive if there exist scalars γ>0, matrices ΛTh=Λh>0(h=1,2,3), PTh=Ph>0, RTh=Rh>0, QTh=Qh>0(h=1,2,,4), TT1=T1>0, ST1=S1>0 and ST2=S2>0, such that the following linear matrix inequalities hold:

    Ξ1=[Σ1,10Σ1,30Σ1,5Σ1,6Σ1,7Σ2,2000Σ3,3Σ3,4000Σ4,4000Σ5,5Σ5,6Σ5,7Σ6,6Σ6,7Σ7,7]<0, (3.2)
    Ξ2=[1,101,301,501,71,81,9Π2,20002,60003,33,4000004,4000005,500006,60007,77,87,98,88,99,9]<0, (3.3)

    where

    Σ1,1=2ATP1AP1+P3+Q1+2δmin(AI)TR1(AI)R1δmin+2(δmaxδmin)(AI)TR2(AI)+2λ1S1,

    Σ1,3=R1δmin,

    Σ1,5=ATP1+δmin(AI)TR1+(δmaxδmin)(AI)TR2Λ3,

    Σ1,6=ATP1θ+δmin(AI)TR1θ+(δmaxδmin)(AI)TR2θ,

    Σ1,7=ATP1θ+δmin(AI)TR1θ+(δmaxδmin)(AI)TR2θ,

    Σ2,2=5DTP2DP3+5τminDTR3D+5(τmaxτmin)DTR4D,

    Σ3,3=Q2Q1R1δminR2δmaxδmin,

    Σ3,4=R2δmaxδmin,

    Σ4,4=Q2R2δmaxδmin,

    Σ5,5=2P1+2δminR1+2(δmaxδmin)R2γΛ3,

    Σ5,6=P1θ+δminR1θ+(δmaxδmin)R2θ,

    Σ5,7=P1θ+δminR1θ+(δmaxδmin)R2θ,

    Σ6,6=2θTP1θ+2δminθTR1θ+2(δmaxδmin)R2θS1,

    Σ6,7=θTP1θ+δminθTR1θ+(δmaxδmin)R2θ,

    Σ7,7=2θTP1θ+2δminθTR1θ+2(δmaxδmin)R2θS1,

    1,1=2CTP2CP2+P4+Q3+2τmin(CI)TR3(CI)R3τmin+2(τmaxτmin)(CI)TR4(CI)+2λ2S2,

    1,3=R3δmin,

    1,5=KΛ1,

    1,7=CTP2+τmin(CI)TR3+(τmaxτmin)(CI)TR4Λ3,

    1,8=CTP2μ+τmin(CI)TR3μ+(τmaxτmin)(CI)TR4μ,

    1,9=CTP2μ+τmin(CI)TR3μ+(τmaxτmin)(CI)TR4μ,

    2,2=P4,

    2,6=KΛ2 3,3=Q3Q4R3τminR4τmaxτmin,

    3,4=R4δmaxδmin,

    4,4=Q4R4τmaxτmin,

    5,5=T12Λ1,

    6,6=5BTP1B+5δminBTR1B+5(δmaxδmin)BTR2BT12Λ2,

    7,7=2P2+2τminR3+2(τmaxτmin)R4γΛ3,

    7,8=P2μ+τminR3μ+(τmaxτmin)R4μ,

    7,9=P2μ+τminR3μ+(τmaxτmin)R4μ,

    8,8=2μTP2μ+2τminμTR3μ+2(δmaxδmin)μTR4μS2,

    8,9=μTP2μ+τminμTR3μ+(δmaxδmin)μTR4μ,

    9,9=2μTP2μ+2τminμTR3μ+2(δmaxδmin)μTR4μS2.

    Proof. Set

    η1(k,i)=m(k+1,i)m(k,i),η2(k,i)=p(k+1,i)p(k,i). (3.4)

    Consider a Lyapunov-Krasovskii functional candidate defined as

    V(k,i)=5g=1Vg(k,i), (3.5)

    where

    V1(k,i)=mT(k,i)P1m(k,i)+pT(k,i)P2p(k,i), (3.6)
    V2(k,i)=k1l=kδ(k)mT(l,i)P3m(l,i)+k1l=kτ(k)pT(l,i)P4p(l,i), (3.7)
    V3(k,i)=k1l=kδminmT(l,i)Q1m(l,i)+kδmin1l=kδmaxmT(l,i)Q2m(l,i)+k1l=kτminpT(l,i)Q3p(l,i)+kτmin1l=kτmaxpT(l,i)Q4p(l,i), (3.8)
    V4(k,i)=1ϑ=δmink1l=k+ϑηT1(l,i)R1η1(l,i)+1ϑ=δmax+δmink1l=kδmin+ϑηT1(l,i)R2η1(l,i)+1ϑ=τmink1l=k+ϑηT2(l,i)R3η2(l,i)+1ϑ=τmax+τmink1l=kτmin+ϑηT2(l,i)R4η2(l,i), (3.9)
    V5(k,i)=k1l=kτ(k)fT(p(l,i))T1f(p(l,i)). (3.10)

    Define ΔV(k,i)=V(k+1,i)V(k,i), then

    ε{ΔV(k,i)}=ε{5i=1ΔVi(k,i)}, (3.11)

    where

    ε{ΔV1(k,i)}=ε{mT(k+1,i)P1m(k+1,i)mT(k,i)P1m(k,i)+pT(k+1,i)P2p(k+1,i)pT(k,i)P2p(k,i)}, (3.12)
    ε{ΔV2(k,i)}=ε{mT(k,i)P3m(k,i)mT(kδ(k),i)P3m(kδ(k),i)+pT(k,i)P4p(k,i)pT(kτ(k),i)P4p(kτ(k),i)}, (3.13)
    ε{ΔV3(k,i)}=ε{mT(k,i)Q1m(k,i)+mT(kδmin,i)(Q2Q1)m(kδmin,i)mT(kδmax,i)Q2m(kδmax,i)+pT(k,i)Q3p(k,i)+pT(kτmin,i)(Q4Q3)p(kτmin,i)pT(kτmax,i)Q4p(kτmax,i)}, (3.14)
    ε{ΔV4(k,i)}=ε{δminηT1(k,i)R1η1(k,i)k1l=kδminηT1(l,i)R1η1(l,i)+(δmaxδmin)ηT1(k,i)R2η1(k,i)kδmin1l=kδmaxηT1(l,i)R2η1(l,i)+τminηT2(k,i)R3η2(k,i)k1l=kτminηT2(l,i)R3η2(l,i)+(τmaxτmin)ηT2(k,i)R4η2(k,i)kδmin1l=kτmaxηT2(l,i)R4η2(l,i)}, (3.15)
    ε{ΔV5(k,i)}=ε{fT(p(k,i))T1f(p(k,i))fT(p(kτ(k),i))T1f(p(kτ(k),i))}. (3.16)

    Taking Eq (3.4) into consideration, for diagonal matrices Λ1>0, Λ2>0, there is

    2pT(k,i)KΛ1f(p(k,i))2fT(p(k,i))Λ1f(p(k,i))0, (3.17)
    2pT(kτ(k),i)KΛ2f(p(kτ(k),i))2fT(p(kτ(k),i))Λ2f(p(kτ(k),i))0. (3.18)

    Using Lemma 2.2, we have

    k1l=kδminηT1(l,i)R1η1(l,i)1δmin[m(k,i)m(kδmin,i)]TR1[m(k,i)m(kδmin,i)], (3.19)
    kδmin1l=kδmaxηT1(l,i)R2η1(l,i)1δmaxδmin[m(kδmin,i)m(kδmax,i)]TR2[m(kδmin,i)m(kδmax,i)], (3.20)
    k1l=kτminηT2(l,i)R3η2(l,i)1τmin[p(k,i)m(kτmin,i)]TR3[p(k,i)p(kτmin,i)], (3.21)
    kτmin1l=kτmaxηT2(l,i)R4η2(l,i)1τmaxτmin[p(kτmin,i)m(kτmax,i)]TR4[p(kτmin,i)p(kτmax,i)]. (3.22)

    The following expression is given to show the passivity property

    J(kp,i)=E{kpk=1[2(mT(k,i)Λ3u(k,i)+pT(k,i)Λ3v(k,i))γ(uT(k,i)Λ3u(k,i)+vT(k,i)Λ3v(k,i))]}, (3.23)

    and it is obvious that

    J(kp,i)=E{kpk=1[ΔV(k,i)2(mT(k,i)Λ3u(k,i)+pT(k,i)Λ3v(k,i))γ(uT(k,i)Λ3u(k,i)+vT(k,i)Λ3v(k,i))]V(kp+1,i)+V(1,i)}E{kpk=1[ΔV(k,i)2(mT(k,i)Λ3u(k,i)+pT(k,i)Λ3v(k,i))γ(uT(k,i)Λ3u(k,i)+vT(k,i)Λ3v(k,i))]+V(1,i)}, (3.24)

    where kN, such that for the original time k0=1, set the initial states of m and p as m(1,i)=p(1,i)=0, so that taking (3.6)–(3.10) into account, we can obtain

    V1(1,i)=V2(1,i)=V3(1,i)=V4(1,i)=V5(1,i)=0. (3.25)

    Considering the spatial continuity and limitations of GRNs, we can obtain

    {mT(k,i+1)S1m(k,i+1)λ1mT(k,i)S1m(k,i)mT(k,i1)S1m(k,i1)λ1mT(k,i)S1m(k,i) (3.26)
    {pT(k,i+1)S2p(k,i+1)λ2pT(k,i)S2p(k,i)pT(k,i1)S2p(k,i1)λ2pT(k,i)S2p(k,i) (3.27)

    where

    λ1=max(max(kNk1),max(kNk1)),λ2=max(max(kNk2),max(kNk2)),
    k1=max(Li=1mT(k,i+1)m(k,i+1)mT(k,i)m(k,i)),k1=max(Li=1mT(k,i1)m(k,i1)mT(k,i)m(k,i)),
    k2=max(Li=1pT(k,i+1)p(k,i+1)pT(k,i)p(k,i)),k2=max(Li=1pT(k,i1)p(k,i1)pT(k,i)p(k,i)).

    Then, by combining Eq (3.11)–(3.27), we can obtain

    E{kpk=1[2(mT(k,i)u(k,i)+pT(k,i)v(k,i))γ(uT(k,i)u(k,i)+vT(k,i)v(k,i))]}E{ξTΞξ}<0, (3.28)

    where ξ=[mT(k,i),mT(kδ(k),i),mT(kδmin,i),mT(kδmax,i),pT(k,i),pT(kτ(k),i),pT(kτmin,i),pT(kτmax,i),fT(p(k,i)),fT(p(kτ(k),i)),uT(k,i),vT(k,i),mT(k,i+1),mT(k,i1),pT(k,i+1),pT(k,i1)].

    This completes the proof.

    Theorem 3.2. For given scalars δ and τ satisfying inequality (2.13), the trivial solution of Eq (2.12) with molecular Brownian motion under Dirichlet boundary conditions is passive if there exist scalars γ>0 and ρ>0, matrices ΛTh=Λh>0(h=1,2), PTh=Ph>0, RTh=Rh>0 and QTh=Qh>0(h=1,,4), TT1=T1>0, ST1=S1>0 and ST2=S2>0, such that the following LMIs hold:

    P1+δminR1+(δmaxδmin)R2ρI, (3.29)
    Θ1=[11013015161718220000003334000044000055565758666768777888]<0, (3.30)
    Θ2=[11013015161718220000003334000044000055000666768777888]<0, (3.31)

    where

    11=ATP1A+δmin(AI)TR1(AI)+(δmaxδmin)(AI)TR2(AI)P1+P3+Q1R1/δmin+2λ1S1,

    13=R1δmin,

    15=ATP1B+δmin(AI)TR1B+(δmaxδmin)(AI)TR2B,

    16=ATP1+δmin(AI)TR1+(δmaxδmin)(AI)TR2+Λ3,

    17=ATP1θ+δmin(AI)TR1θ+(δmaxδmin)(AI)TR2θ,

    18=ATP1θ+δmin(AI)TR1θ+(δmaxδmin)(AI)TR2θ,

    22=3DTP2DP3+3τminDTR3D+3(τmaxτmin)DTR4D,

    33=Q2Q1R1δminR2τmaxτmin,

    34=R2δmaxδmin,

    44=Q2R2δmaxδmin,

    55=BTP1B+δminBTR1B+(δmaxδmin)BTR2BT1+Λ2,

    56=BTP1+δminBTR1+(δmaxδmin)BTR2,

    57=BTPθ+δminBTR1θ+(δmaxδmin)BTR2θ,

    58=BTPθ+δminBTR1θ+(δmaxδmin)BTR2θ,

    66=P1+δminR1+(δmaxδmin)R2γΛ3,

    67=P1θ+δminR1θ+(δmaxδmin)R2θ,

    68=P1θ+δminR1θ+(δmaxδmin)R2θ,

    77=θTP1θ+δminθTR1θ+(δmaxδmin)θTR2θS1,

    78=θTP1θ+δminθTR1θ+(δmaxδmin)θTR2θ,

    88=θTP1θ+δminθTR1θ+(δmaxδmin)θTR2θS1,

    Π11=2CTP2CP2+P4+Q3+2τmin(CI)TR3(CI)R3/τmin+2(τmaxτmin)(CI)TR4(CI)+ρH1+2λ2S2,

    13=R3/τmin,

    15=KΛ1,

    16=CTP2+τmin(CI)TR3+(τmaxτmin)(CI)TR4+Λ3,

    17=CTP2μ1+τmin(CI)TR3μ1+(τmaxτmin)(CI)TR4μ1,

    18=CTP2μ2+τmin(CI)TR3μ2+(τmaxτmin)(CI)TR4μ2,

    22=P4+KTΛ2K+ρH2,

    33=Q3Q4R3/τminR4/(τmaxτmin),

    34=R4/(τmaxτmax),

    44=Q4R4/(τmaxτmin),

    55=2Λ1+T1,

    66=P2+τmaxR3+(τmaxτmin)R4γΛ3,

    67=P2μ+τminR3μ+(τmaxτmin)R4μ,

    68=P2μ+τminR3μ+(τmaxτmin)R4μ,

    77=μTP2μ+τminμTR3μ+(τmaxτmin)μTR4μS2,

    78=μTP2μ+τminμTR3μ+(τmaxτmin)μTR4μ,

    88=μTP2μ+τminμTR3μ+(τmaxτmin)μTR4μS2.

    Proof. Using Lemma 2.3, we have

    {2pT(k,i)CTP2Dm(kδ(k),i)pT(k,i)CTP2Cp(k,i)+mT(kδ(k),i)DTP2Dm(kδ(k),i)2mT(kδ(k),i)DTP2D2v(k,i)mT(kδ(k),i)DTP2Dm(kδ(k),i)+vT(k,i)DT2P2D2v(k,i)2τminpT(k,i)(CI)TR3Dm(kδ(k),i)τminpT(k,i)(CI)TR3(CI)p(k,i)+τminmT(kδ(k),i)DTR3Dm(kδ(k),i)2τminmT(kδ(k),n)DTR3v(k,n)τminmT(kδ(k),i)DTR3Dm(kδ(k),i)+τminvT(k,i)R3v(k,i)2(τmaxτmin)pT(k,i)(CI)TR4Dm(kδ(k),i)(τmaxτmin)pT(k,i)(CI)TR4(CI)p(k,i)+(τmaxτmin)mT(kδ(k),i)DTR4Dm(kδ(k),i)2(τmaxτmin)mT(kδ(k),i)DTR4v(k,i)(τmaxτmin)mT(kδ(k),i)DTR4Dm(kδ(k),i)+(τmaxτmin)vT(k,n)R4v(k,i)2pT(kτ(k),i)KΛ2f((pi(kτ(k),i))pT(kτ(k),i)KTΛ2Kp(kτ(k),i)+f((p(kτ(k),i))Λ2f((p(kτ(k),i)). (3.32)

    Noting Inequality (2.13), it can be seen that

    σT(p(k,i),p(kτ(k),i))[P1+δminR1+(δmaxδmin)R2]σ(p(k,i),p(kτ(k),i))ρpT(k,i)H1p(k,i)+ρpT(kτ(k),i)H2p(kτ(k),i). (3.33)

    Then combining Eqs (3.11) to (3.25) with Eqs (3.32) and (3.33), we get

    E{kpk=1[2(mT(k,i)u(k,i)+pT(k,i)v(k,i))γ(uT(k,i)u(k,i)+vT(k,i)v(k,i))]}E{ξT1Θ1ξ1+ξT2Θ2ξ2}<0, (3.34)

    where

    ξ1=[mT(k,i),mT(kδ(k),i),mT(kδmin,i),mT(kδmax,i),fT(p(kτ(k),i)),uT(k,i),mT(k,i+1),mT(k,i1)],

    ξ2=[pT(k,i),pT(kτ(k),i),pT(kτmin,i),pT(kτmax,i),fT(p(k,i)),vT(k,i),pT(k,i+1),pT(k,i1)].

    The proof of the theorem is now complete.

    Remark 3.3. In real genetic regulatory networks, the functions and operations of mRNA and proteins are often affected by noise, which includes physical noise and biological noise. Among these, Brownian motion represents a form of physical noise that arises from the random movements of large molecules such as mRNA and proteins within the cell. This randomness contributes to fluctuations in molecular concentrations and interactions, thereby affecting the overall functionality and stability of the network. Theorem 3.1 presents a foundational understanding of these networks without accounting for certain types of noise. In contrast, Theorem 3.2 takes into account the impact of physical noise generated by Brownian motion on the passivity of the model to a greater extent. This not only enhances the model's predictive power but also provides deeper insights into the role of physical noise in shaping network behavior.

    In this section, we demonstrate the validity of Theorems 3.1 and 3.2 through two examples. Example 4.1 showcases the passivity of the proposed GRNs model without Brownian motion, while Example 4.2 illustrates the passivity of the proposed GRNs model with Brownian motion included.

    Example 4.1. In this section, we consider a GRN (2.12) with 5 nodes, L=100. The parameters are assumed to be

    A=C=diag(0.1,0.1,0.1,0.1,0.1),D=(0.8,0.8,0.8,0.8,0.8),

    B=[00.50.5000.5000.50.500.50000.50.50000000.50],K=[0.65000000.65000000.65000000.65000000.65].

    u1(k,i)=0.5(1iL2L2)2sin(2k)×m1(k,i), u2(k,i)=0.5(1.2iL2L2)2cos(2k)×m2(k,i),

    u3(k,i)=0.5(0.5iL2L2)2sin(k)×m3(k,i), u4(k,i)=0.5(0.2iL2L2)2cos(0.2k)×m4(k,i),

    u5(k,i)=0.5(0.5iL2L2)2sin(0.3k)×m5(k,i), v1(k,i)=0.5(1.2iL2L2)2sin(3k)×p1(k,i),

    v2(k,i)=0.5(1iL2L2)2cos(k)×p2(k,i), v3(k,i)=0.5(0.7iL2L2)2cos(2k)×p3(k,i),

    v4(k,i)=0.5(1iL2L2)2cos(k)×p4(k,i), v5(k,i)=0.5(0.7iL2L2)2cos(2k)×p5(k,i),

    where f(x)=x2/(1+x2), the time delays δ(k)=4+2sin(kπ/2) and τ(k)=4+sin(kπ/2), so that δmin=2, δmax=6, τmin=3, τmax=5, coupling coefficient θ=μ=0.2.

    The simulation result of trajectories of mRNA and protein concentrations for Example 4.1 are shown in Figures 26.

    Figure 2.  The trajectory of m1(k,i) and p1(k,i).
    Figure 3.  The trajectory of m2(k,i) and p2(k,i).
    Figure 4.  The trajectory of m3(k,i) and p3(k,i).
    Figure 5.  The trajectory of m4(k,i) and p4(k,i).
    Figure 6.  The trajectory of m5(k,i) and p5(k,i).

    If ϕ1=ϕ2=ϕ{0.1,0.3,0.5,0.7,0.9,1.0}, ϕ1=ϕ2=ϕ>1. The maximum delay τmax=δmax is obtained based on ([21], Theorem 1), ([25], Remark 2), ([22], Theorem 1), and Theorem 3.1; the following illustrations are made for Table 1:

    ● If μ0.7, the LMI conditions outlined in ([21], Theorem 1), ([25], Remark 2), ([22], Theorem 1), and Theorem 3.1 are considered to be achievable.

    ● When μ=0.9, the LMI conditions given in ([22], Theorem 1) are feasible, but the LMI conditions presented in ([21], Theorem 1), ([25], Remark 2), and Theorem 3.1 are .

    ● When μ=1, the LMI conditions discussed in ([21], Theorem 1) and ([25], Remark 2) are feasible, the LMI conditions discussed in ([22], Theorem 1) are unfeasible, and only the LMI conditions discussed in Theorem 3.1 are .

    Table 1.  Upper bounds on τmax=δmax with different ϕ.
    Case 0.1 0.3 0.5 0.7 0.9 1.0
    ([21], Theorem 1) 3.9616
    ([25], Remark 2) 5.4571
    ([22], Theorem 1) 2.8994 \
    Theorem 3.1

     | Show Table
    DownLoad: CSV

    Therefore, within the range of μ1, Theorem 3.1 of this paper exhibits a reduced level of conservativeness compared to ([21], Theorem 1), ([25], Remark 2), and ([22], Theorem 1).

    Example 4.2. Considering the Brownian motion for GRNs (2.12), H1=H2=1, λ1=λ2=2, by using the Toolbox YALMIP in MATLAB to solve the LMIs (3.2) and (3.3), we can obtain the following feasible solution:

    P1=[1.35760.07300.49010.29580.03140.07301.03780.14990.40160.45980.49010.14992.20790.58610.07000.29580.40160.58611.55410.17950.03140.45980.07000.17951.8931],
    P2=[2.96980.00090.02510.02370.00060.00092.89230.00160.02610.02560.02510.00163.09360.02600.00070.02370.02610.02603.04360.00230.00060.02560.00070.00232.9869],
    P3=[0.13860.00580.03700.0200.00280.00580.11320.01240.03080.03560.03700.01240.20660.04480.00590.02070.03080.04480.15540.01480.00280.03560.00590.01480.1789],
    P4=[0.57730.00290.00120.00290.00500.00290.60930.00360.00030.00120.00120.00360.55150.00010.00040.00290.00030.00010.61050.00450.00500.00120.00040.00450.5039],
    R1=[0.01410.00090.00590.00320.00040.00090.01050.00210.00490.00560.00590.00210.02500.00740.00110.00320.00490.00740.01670.00250.00040.00560.00110.00250.0204],
    R2=[0.01070.00060.00440.00240.00030.00060.00800.00160.00370.00420.00440.00160.01890.00550.00090.00240.00370.00550.01270.00190.00030.00420.00090.00190.0155],
    R3=[0.06080.00060.00070.00030.00120.00060.05710.00080.00050.00010.00070.00080.06660.00040.00010.00030.00050.00040.06170.00100.00120.00010.00010.00100.0654],
    R4=[0.02620.00040.00030.00030.00070.00040.02410.00050.00020.00000.00030.00050.02950.00020.00010.00030.00020.00020.02660.00070.00070.00000.00010.00070.0290],
    Q1=[0.17890.01060.06800.04110.00440.01060.13030.02060.05750.06590.06800.02060.29580.08030.00920.04110.05750.08030.20550.02440.00440.06590.00920.02440.2528],
    Q2=[0.12060.00690.04440.02740.00280.00690.08820.01300.03760.04300.04440.01300.19570.05190.00560.02740.03760.05190.13750.01540.00280.04300.00560.01540.1688],
    Q3=[0.09670.00270.00110.00270.00450.00270.08540.00330.00030.00110.00110.00330.11280.00010.00040.00270.00030.00010.09670.00410.00450.00110.00040.00410.1130],
    Q4=[0.75970.00050.00020.00060.00090.00050.75750.00070.00000.00030.00020.00070.76280.00000.00010.00060.00000.00000.75960.00080.00090.00030.00010.00080.7630],
    Λ1=diag(0.5739,0.5596,0.5650,0.5694,0.5711),
    Λ2=diag(0.7148,0.7849,0.6454,0.7673,0.5683),
    Λ3=diag(0.4336,0.4259,0.4491,0.4452,0.4326),
    T1=[0.47610.05090.02970.03600.08210.05090.47770.06130.00940.02210.02970.06130.46980.00610.01220.03600.00940.00610.48080.07050.08210.02210.01220.07050.4545],
    S1=[0.22400.01230.08360.05180.00510.01230.17040.02470.06780.07750.08360.02470.36660.09950.01130.05180.06780.09950.25640.02970.00510.07750.01130.02970.3157],
    S2=[0.47360.00160.00710.00460.00250.00160.45360.00150.00680.00590.00710.00150.50250.00670.00010.00460.00680.00670.48350.00180.00250.00590.00010.00180.4883],
    γ=0.7430,ρ=0.0119.

    Therefore, it can be concluded by Examples 4.1 and 4.2 that Eq (2.8) is stochastically passive.

    Figure 7 presents the boundary between the passive and non-passive behavior regions of the proposed GRN model at μ=0.55 and θ=0.60. It can be clearly observed that when the values of the coupling coefficients θ and μ fall within the parameter range defined by Region Ⅰ, specifically 0.05μ0.55 and 0.05θ0.60, the proposed discrete-time gene regulatory network model exhibits passive behavior. Conversely, when the values of θ and μ fall within the range defined by Region Ⅱ, the proposed GRN model does not exhibit passive behavior. The dashed line in Figure 7 precisely delineates the boundary between the regions of passivity and non-passivity, distinguishing Region Ⅰ from Region Ⅱ. This boundary was determined through extensive computer software simulations, identifying the critical values of θ and μ at which the system transitions from passive to non-passive behavior. The shapes of the regional boundaries reflect the complex interplay between the model parameters and their impact on the system's passivity properties.

    Remark 4.3. In real biological environments, the concentrations of mRNA and proteins are indeed influenced by a wide array of factors, including gene mutations, interactions between cells, biological enzymes, hormone levels, and environmental conditions. These factors contribute to the complex dynamics and heterogeneity observed in biological systems. However, our proposed model focuses on a more simplified mathematical representation of these processes, specifically considering the interactions between mRNA and proteins, the effects of spatial diffusion terms, and the impact of time delays on their concentrations. While this mathematical simplification allows us to derive analytical results and gain insights into the passivity and stability of the system, it also introduces limitations in the model's ability to fully capture the complexity of real biological environments. For instance, our model does not account for the potential effects of gene mutations or the intricate interactions between cells in a tissue or organ. Additionally, we do not consider the role of biological enzymes or hormone levels, which can significantly impact gene expression and protein synthesis.

    Figure 7.  Determining the passivity of Eq (2.13) under different coupling coefficients.

    It is important to recognize these limitations and to understand that our model represents a first step toward understanding the dynamics of gene regulatory networks in a mathematical framework. Future work could build upon our findings by incorporating additional factors that contribute to the complexity of real biological systems. Such extensions could provide even deeper insights into the mechanisms underlying gene expression and protein synthesis, as well as their implications for health and disease.

    In this groundbreaking study, we propose a pioneering approach to reaction-diffusion mechanisms into discrete-time GRNs. Our primary focus is to explore the robust passivity of these networks under the influence of time-varying delay and Dirichlet boundary conditions using advanced Lyapunov-Krasovskii functions. Moreover, we delve into the investigation of asymptotic passivity for GRNs that incorporate reaction-diffusion terms along with Brownian motion. This unique exploration is unprecedented and marks the first-ever attempt to introduce reaction-diffusion into discrete-time GRNs. To demonstrate the efficacy and validity of our novel method, we present comprehensive numerical examples and simulation results. These findings showcase the correctness and effectiveness of our approach, solidifying its potential impact on the field of gene regulatory network modeling and analysis. In the future, the asynchronous behavior of discrete-time systems with reaction-diffusion coupling could be studied, in order to understand how different update schedules affect the passivity and stability of the network. In addition, we can also try to extend the proposed model to more complex spatial domains, such as those with irregular geometries or anisotropic diffusion, which will provide further insights into the spatial organization of gene regulatory networks.

    The authors declare they have not used Artificial Intelligence (AI) tools in the creation of this article.

    This research was funded by Post-doctoral Natural Science Foundation of China under grant number 2022M720650.

    The authors declare there is no conflicts of interest.

    [1] Okano H, Kaneko S, Okada S, et al. (2007) Regeneration-based therapies for spinal cord injuries. Neurochem Int 51: 68–73. doi: 10.1016/j.neuint.2007.04.013
    [2] Okano H, Sakaguchi M, Ohki K, et al. (2007) Regeneration of the central nervous system using endogenous repair mechanisms. J Neurochem 102: 1459–1465. doi: 10.1111/j.1471-4159.2007.04674.x
    [3] Okita K, Ichisaka T, Yamanaka S (2007) Generation of germ-line competent induced pluripotent stem cells. Nature 448: 313–317. doi: 10.1038/nature05934
    [4] Berker RA, Barrett J, Mason SL, et al. (2013) Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease. Lancet Neurol 12: 84–91. doi: 10.1016/S1474-4422(12)70295-8
    [5] Horita Y, Honmou O, Harada K, et al. (2006) lntravenous administration of glial cell line derived neutrophic factor gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat. J Neurosci Res 84: 1495–1504. doi: 10.1002/jnr.21056
    [6] Morizane A, Doi D, Kikuchi T, et al. (2013) Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a nonhuman primate. Stem Cell Reports 1: 283–292. doi: 10.1016/j.stemcr.2013.08.007
    [7] Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. (1998) Embryonic Stem Cell Lines Derived from Human. Science 282: 1145–1147.
    [8] Beyer Nardi N, da Silva Meirelles L (2006) Mesenchymal stem cells: isolation, in vitro expansion and characterization. Handb Exp Pharmacol 174: 249–282. doi: 10.1007/3-540-31265-X_11
    [9] Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663–676. doi: 10.1016/j.cell.2006.07.024
    [10] Guzman R, Choi R, Gera A, et al. (2008) Intravascular cell replacement therapy for stroke. Neurosurg Focus 24: E15.
    [11] Matsushita T, Kibayashi T, Katayama T, et al. (2011) Mesenchymal stem cells transmigrate across brain microvascular endothelial cell monolayers through transiently formed inter-endothelial gaps. Neurosci Lett 502: 41–45. doi: 10.1016/j.neulet.2011.07.021
    [12] Steingen C, Brenig F, Baumgartner L, et al. (2008) Characterization of key mechanisms in transmigration and invasion of mesenchymal stem cells. J Mol Cell Cardiol 44: 1072–1084. doi: 10.1016/j.yjmcc.2008.03.010
    [13] Baldwing A (2009) Morality and human embryo research. Introduction to the Talking Point on morality and human embryo research. EMBO Reports 10: 299–300.
    [14] Henderson JK, Draper JS, Baillie HS, et al. (2002) Preimplantation human embryos and embryonic stem cells show comparable expression of stage-specific embryonic antigens. Stem Cells 20: 329–337. doi: 10.1634/stemcells.20-4-329
    [15] Hedlund E, Pruszak J, Lardaro T, et al. (2008) Embryonic stem cell-derived Pitx3-enhanced green fluorescent protein midbrain dopamine neurons survive enrichment by fluorescence-activated cell sorting and function in an animal model of Parkinson's disease. Stem Cells 26: 1526–1536. doi: 10.1634/stemcells.2007-0996
    [16] Dominici M, Le Blanc K, Mueller I, et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315–317.
    [17] Valero MC, Huntsman HD, Liu J, et al. (2012) Eccentric exercise facilitates mesenchymal stem cell appearance in skeletal muscle. PLoS One 7: e29760. doi: 10.1371/journal.pone.0029760
    [18] Wang S, Qu X, Zhao RC. (2012) Clinical applications of mesenchymal stem cells. J Hematol Oncol 5: 19. doi: 10.1186/1756-8722-5-19
    [19] Lalu MM, McIntyre L, Pugliese C, et al. (2012) Canadian Critical Care Trials Group. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One 7: e47559.
    [20] Mabuchi Y, Morikawa S, Harada S, et al. (2013) LNGFR(+)THY-1(+)VCAM-1(hi+) cells reveal functionally distinct subpopulations in mesenchymal stem cells. Stem Cell Reports 1: 152–165. doi: 10.1016/j.stemcr.2013.06.001
    [21] Morikawa S, Mabuchi Y, Kubota Y, et al. (2009) Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. J Exp Med 206: 2483–2496. doi: 10.1084/jem.20091046
    [22] Aggarwal S, Pittenger MF (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105: 1815–1822. doi: 10.1182/blood-2004-04-1559
    [23] Arinzeh TL, Peter SJ, Archambault MP, et al. (2003) Allogeneic mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect. J Bone Joint Surg Am 85: 1927–1935. doi: 10.2106/00004623-200310000-00010
    [24] Farini A, Sitzia C, Erratico S, et al. (2014) Clinical applications of mesenchymal stem cells in chronic diseases. Stem Cells Int 2014: 306573.
    [25] Le Blanc K, Rasmusson I, Sundberg B, et al. (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363: 1439–1441. doi: 10.1016/S0140-6736(04)16104-7
    [26] Tobin LM, Healy ME, English K, et al. (2013) Human mesenchymal stem cells suppress donor CD4(+) T cell proliferation and reduce pathology in a humanized mouse model of acute graft-versus-host disease. Clin Exp Immunol 172: 333–348. doi: 10.1111/cei.12056
    [27] Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al. (2010) Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 67: 1187–1194.
    [28] von Bahr L, Batsis I, Moll G, et al. (2012) Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells 30: 1575–1578. doi: 10.1002/stem.1118
    [29] Takahashi K, Tanabe K, Ohnuki M, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861–872. doi: 10.1016/j.cell.2007.11.019
    [30] Johannesson B, Sagi I, Gore A, et al. (2014) Comparable frequencies of coding mutations and loss of imprinting in human pluripotent cells derived by nuclear transfer and defined factors. Cell Stem Cell 15: 634–642. doi: 10.1016/j.stem.2014.10.002
    [31] Ma H, Morey R, O'Neil RC, et al. (2014) Abnormalities in human pluripotent cells due to reprogramming mechanisms. Nature 511: 177–183. doi: 10.1038/nature13551
    [32] Okita K, Yamakawa T, Matsumura Y, et al. (2013) An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells 31: 458–466. doi: 10.1002/stem.1293
    [33] Warren L, Manos PD, Ahfeldt T, et al. (2010) Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7: 618–630. doi: 10.1016/j.stem.2010.08.012
    [34] McDonald JW, Liu XZ, Qu Y, et al. (1999) Transplanted embryonic stem cells survive, differentiate and promote recovery in injured rat spinal cord. Nat Med 5: 1410–1412. doi: 10.1038/70986
    [35] Yu J, Vodyanik MA, Smuga-Otto K, et al. (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917–1920. doi: 10.1126/science.1151526
    [36] Hayashi Y, Chan T, Warashina M, et al. (2010) Reduction of N-glycolylneuraminic acid in human induced pluripotent stem cells generated or cultured under feeder-and serum-free defined conditions. PLoS One 5: e14099. doi: 10.1371/journal.pone.0014099
    [37] Miyazaki T, Futaki S, Suemori H, et al. (2012) Laminin E8 fragments support efficient adhesion and expansion of dissociated human pluripotent stem cells. Nat Commun 3: 1236. doi: 10.1038/ncomms2231
    [38] Rodin S, Domogatskaya A, Ström S, et al. (2010) Long-term self-renewal of human pluripotent stem cells on human recombinant laminin-511. Nat Biotechnol 28: 611–615. doi: 10.1038/nbt.1620
    [39] Morita T, Sasaki M, Kataoka-Sasaki Y, et al. (2016) Intravenous infusion of mesenchymal stem cells promotes functional recovery in a model of chronic spinal cord injury. Neuroscience 335: 221–231. doi: 10.1016/j.neuroscience.2016.08.037
    [40] Nakajima F, Tokunaga K, Nakatsuji N (2007) Human leukocyte antigen matching estimations in a hypothetical bank of human embryonic stem cell lines in the Japanese population for use in cell transplantation therapy. Stem Cells 25: 983–985. doi: 10.1634/stemcells.2006-0566
    [41] Guo XL, Chen JS (2015) Research on induced pluripotent stem cells and the application in ocular tissues. Int J Ophthalmol 8: 818–825.
    [42] Chambers SM, Fasano CA, Papapetrou EP, et al. (2009) Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 27: 275–280. doi: 10.1038/nbt.1529
    [43] Doi D, Morizane A, Kikuchi T, et al. (2012) Prolonged maturation culture favors a reduction in the tumorigencity and the dopaminergic function of human ESC-derived neural cells in a primate model of Parkinson's disease. Stem Cells 30: 935–945. doi: 10.1002/stem.1060
    [44] Kikuchi T, Morizane A, Doi D, et al. (2011) Survival of human induced pluripotent stem cell-derived midbrain dopaminergic neurons in the brain of a primate model of parkinson's disease. J Parkinsons Dis 1: 395–412.
    [45] Kriks S, Shim JW, Piano J, et al. (2011) Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 480: 547–551. doi: 10.1038/nature10648
    [46] Brederlau A, Correia AS, Anisimov SV, et al. (2006) Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: effect of in vitro differentiation on graft survival and teratoma formation. Stem Cells 24: 1433–1440. doi: 10.1634/stemcells.2005-0393
    [47] Grealish S, Diguet E, Kirkeby A, et al. (2014) Human EsC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons wihen grafted in a rat model of Parkinson's disease. Cell stem Cell 15: 653–665. doi: 10.1016/j.stem.2014.09.017
    [48] Hayashi T, Wakao S, Kitada M, et al. (2013) Autologous mesenchymal stem cell-derived dopaminergic neurons function in parkinsonian macaques. J Clin Invest 123: 272–284. doi: 10.1172/JCI62516
    [49] Argus G, Cooper O, Deleidi M, et al. (2010) Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci 107: 15921–15926. doi: 10.1073/pnas.1010209107
    [50] Rhee YH,Ko JY, Chang MY, et al. (2011) Protein-based human iPS cells efficient1y generate functional dopamine neurons and can treata rat model of Parkinson disease. J Clin Invest 121: 2326–2335. doi: 10.1172/JCI45794
    [51] Kikuchi T, Morizane A, Doi D, et al. (2017) Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model. Nature 548: 592–596. doi: 10.1038/nature23664
    [52] Barker RA, Drouin-Quellet J, Parmar M (2015) Cell-based therapies for Parkinson disease-past insights and future potential. Nat Rev Neurol 11: 492–503. doi: 10.1038/nrneurol.2015.123
    [53] Yan Liu, Jason P Weick, Huisheng Liu, et al. (2013) Medial ganglionic eminence–like cells derived from human embryonic stem cells correct learning and memory deficits. Nat Biotechnol 31: 440–447. doi: 10.1038/nbt.2565
    [54] Lee H, Shamy GA, Elkabetz Y, et al. (2007) Directed differentiation and transplantation of human embryonic stem cell-derived motoneurons. Stem Cells 25: 1931–1939. doi: 10.1634/stemcells.2007-0097
    [55] Lee JK, Jin HK, Bae JS (2010) Bone marrow-derived mesenchymal stem cells attenuate amyloid beta-induced memori impairment and apoptosis by inhibiting neuronal cell death. Curr Alzheimer Res 7: 540–548. doi: 10.2174/156720510792231739
    [56] Takamatsu K, Ikeda T, Haruta M, et al. (2014) Degradation of amyloid beta by human induced pluripotent stem cell-derived macrophages expressing Neprilysin-2. Stem Cell Res 13: 442–453. doi: 10.1016/j.scr.2014.10.001
    [57] Lee HJ, Lee JK, Lee H, et al. (2010) The therapeutic potential of human umbilical cord blood-derived mesenchymal stem cells in Alzheimer's disease. Neurosci Lett 481: 30–35. doi: 10.1016/j.neulet.2010.06.045
    [58] Harper JM, Krishnan C, Darman JS, et al. (2004) Axonal growth of embryonic stem cell-derived motoneurons in vitro and in motoneuron-injured adult rats. Proc Natl Acad Sci U S A 101: 7123–7128. doi: 10.1073/pnas.0401103101
    [59] Kerr DA, Lladó J, Shamblott MJ, et al. (2003) Human embryonic germ cell derivatives facilitate motor recovery of rats with diffuse motor neuron injury. J Neurosci 23: 5131–5140.
    [60] Lepore AC, Rauck B, Dejea C, et al. (2008) Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat Neurosci 11: 1294–1301. doi: 10.1038/nn.2210
    [61] Kawada J, Kaneda S, Kirihara T, et al. (2017) Generation of a Motor Nerve Organoid with Human Stem Cell-Derived Neurons. Stem Cell Reports 14: 1441–1449.
    [62] Aubry L, Bugi A, Lefort N, et al. (2008) Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats. Proc Natl Acad Sci U S A 105: 16707–16712. doi: 10.1073/pnas.0808488105
    [63] Lee ST, Chu K, Jung KH, et al. (2009) Slowed progression in models of Huntington disease by adipose stem cell transplantation. Ann Neurol 66: 671–681. doi: 10.1002/ana.21788
    [64] Chae JI, Kim DW, Lee N, et al. (2012) Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient. Biochem J 446: 359–371. doi: 10.1042/BJ20111495
    [65] Cicchetti F, Saporta S, Hauser RA, et al. (2009) Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proc Natl Acad Sci U S A 106: 12483–12488. doi: 10.1073/pnas.0904239106
    [66] Freeman TB, Cicchetti F, Hauser RA, et al. (2000) Transplanted fetal striatum in Huntington's disease:phenotypic development and lack of pathology. Proc Natl Acad Sci U S A 97: 13877–13882. doi: 10.1073/pnas.97.25.13877
    [67] Keene CD, Chang RC, Leverenz JB, et al. (2009) A patient with Huntington's disease and long-surviving fetal neural transplants that developed mass lesions. Acta Neuropathol 117: 329–338. doi: 10.1007/s00401-008-0465-0
    [68] Takagi Y, Hashimoto N (2006) Transplantation of embryonic stem cell-derived neural progenitors into ischemic brain. Nosotchu 28: 600–605. doi: 10.3995/jstroke.28.600
    [69] Hayashi J, Takagi Y, Fukuda H, et al. (2006) Primate embryonic stem cell-derived neuronal progenitors transplanted into ischemic brain. J Cereb Blood Flow Metab 26: 906–914. doi: 10.1038/sj.jcbfm.9600247
    [70] Chen S J, Chang CM, Tsai SK, et al. (2010) Functional improvementof focal cerebral ischemia injury by subdural transplantationof induced pluripotent stem cells with fibrin glue. Stem Cells Dev 19: 1757–1767. doi: 10.1089/scd.2009.0452
    [71] Suzuki J, Sasaki M, Harada K, et al. (2013) Bilateral cortical hyperactivity detencted by fMRI associates with improved motor function following intravenous infusion of mesenchymal stem cells in a rat stroke model. Brain Res 1497: 15–22. doi: 10.1016/j.brainres.2012.12.028
    [72] García R, Aguiar J, Alberti E, et al. (2004) Bone marrow stromal cells produce nerve growth factor and glial cell line-derived neurotrophic factors. Biochem Biophys Res Commun 316: 753–754. doi: 10.1016/j.bbrc.2004.02.111
    [73] Nomura T, Honmou O, Harada H, et al. (2005) Infusion of BDNF gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat. Neuroscience 136: 161–169. doi: 10.1016/j.neuroscience.2005.06.062
    [74] Onda T, Honmou O, Harada K, et al. (2008) Therapeutic benefits by human mesenchymal stem cells(hMSs) and Ang-1 gene-modifeied hMSCs after cerebral ischemia. J Cereb Blood Flow Metab 28: 329–340. doi: 10.1038/sj.jcbfm.9600527
    [75] Savitz SI, Chopp M, Deans R, et al. (2011) STEPS Participants: Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II. Stroke 42: 825–829. doi: 10.1161/STROKEAHA.110.601914
    [76] Uemura M, Kasahara Y, Nagatsuka K, et al. (2012) Cell-based therapy to promote angiogenesis in the brain following ischemic damage. Curr Vasc Pharmacol 10: 285–288. doi: 10.2174/157016112799959369
    [77] Hermanto Y, Sunohara T, Faried A, et al. (2017) Transplantation of feeder-free human induced pluripotent stem cell-derived cortical neuron progenitors in adult male Wistar rats with focal brain ischemia. J Neurosci Res 96: 863–874.
    [78] Honmou O, Houkin K, Matsunaga T, et al. (2011) Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain 134: 1790–1807. doi: 10.1093/brain/awr063
    [79] Steinberg GK, Kondziolka D, Wechsler LR, et al. (2016) Clinical Outcomes of Transplanted Modified Bone Marrow-Derived Mesenchymal Stem Cells in Stroke: A Phase 1/2a Study. Stroke 47: 1817–1824. doi: 10.1161/STROKEAHA.116.012995
    [80] Kumagai G, Okada Y, Yamane J, et al. (2009) Roles of ES cell-derived gliogenic neural stem/progenitor cells in functional recovery after spinal cord injury. PLoS One 4: e7706. doi: 10.1371/journal.pone.0007706
    [81] Erceg S, Ronaghi M, Oria M, et al. (2010) Transplanted oligodendrocytes and motoneuron progenitors generated from human embryonic stem cells promote locomotor recovery after spinal cord transaction. Stem Cells 28: 1541–1549. doi: 10.1002/stem.489
    [82] Keirstead HS, Nistor G, Bernal G, et al. (2005) Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J Neurosci 25: 4694–4705. doi: 10.1523/JNEUROSCI.0311-05.2005
    [83] Osaka M, Honmou O, Murakami T, et al. (2010) Intravenous administration of mesenchymal stem cells derived from bone marrow after contusive spinal cord injury improves functional outcome. Brain Res 9: 226–235.
    [84] Müller FJ, Snyder EY, Loring JF (2006) Gene therapy: can neural stem cells deliver? Nat Rev Neurosci 7: 75–84. doi: 10.1038/nrn1829
    [85] Tsuji O, Miura K, Okada Y, et al. (2010) Therapeutic potential of appropriately evaluated safe-induced pluripotent stem cells for spinal cord injury. Proc Natl Acad Sci U S A 107: 12704–12709. doi: 10.1073/pnas.0910106107
    [86] Fujimoto Y, Abematsu M, Falk A, et al. (2012) Treatment of a mouse model of spinal cord injury by transplantation of human induced pluripotent stem cell-derived long-term self-renewing neuroepithelial-like stem cells. Stem Cells 30: 1163–1173. doi: 10.1002/stem.1083
    [87] Nori S, Okada Y, Yasuda A, et al. (2011) Grafted human-induced pluripotent stem-cell-derived neurospheres promote motor functional recovery after spinal cord injury in mice. Proc Natl Acad Sci U S A 108: 16825–16830.
    [88] Kobayashi Y, Okada Y, Itakura G, et al. (2012) Pre-evaluated safe human iPSC-derived neural stem cells promote functional recovery after spinal cord injury in common marmoset without tumorigenicity. PLoS One 7: e52787. doi: 10.1371/journal.pone.0052787
    [89] Nishimura S, Yasuda A, Iwai H, et al. (2013) Time-dependent changes in the microenvironment of injured spinal cord affects the therapeutic potential of neural stem cell transplantation for spinal cord injury. Mol Brain 6: 3. doi: 10.1186/1756-6606-6-3
    [90] Kuroda Y, Kitada M, Wakao S, et al. (2011) Bone marrow mesenchymal cells: how do they contribute to tissue repair and are they really stem cells? Arch lmmunol Ther Exp 59: 369–378. doi: 10.1007/s00005-011-0139-9
    [91] Yoon SH, Shim YS, Park YH, et al. (2007) Complete spinal cord injury treatment using autologous bone marrow cell transplantation and bone marrow stimulation with granulocyte macrophage-colony stimulating factor: Phase I/II clinical trial. Stem Cells 25: 2066–2073. doi: 10.1634/stemcells.2006-0807
    [92] Riess P, Molcanyi M, Bentz K, et al. (2007) Embryonic stem cell transplantation after experimental traumatic brain injury dramatically improves neurological outcome, but may cause tumors. J Neurotrauma 24: 216–225. doi: 10.1089/neu.2006.0141
    [93] Tajiri N, Duncan K, Antoine A, et al. (2014) Stem cell-paved biobridge facilitates neural repair in traumatic brain injury. Front Syst Neurosci 8: 116.
    [94] Tian C, Wang X, Wang X, et al. (2013) Autologous bone marrow mesenchymal stem cell therapy in the subacute stage of traumatic brain injury by lumbar puncture. Exp Clin Transplant 11: 176–181. doi: 10.6002/ect.2012.0053
    [95] Stupp R, Mason WP, van den Bent MJ, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987–996. doi: 10.1056/NEJMoa043330
    [96] Stupp R, Brada M, van den Bent MJ, et al. (2014) ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25: 93–101.
    [97] Kim SU (2011) Neural stem cell-based gene therapy for brain tumors. Stem Cell Rev 7: 130–140. doi: 10.1007/s12015-010-9154-1
    [98] Rainov N (2000) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11: 2389401.
    [99] Nakamura K, Ito Y, Kawano Y, et al. (2004) Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 11: 1155–1164. doi: 10.1038/sj.gt.3302276
    [100] Stagg J, Lejeune L, Paquin A, et al. (2004) Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy. Hum Gene Ther 15: 597–608. doi: 10.1089/104303404323142042
    [101] Yuan X, Hu J, Belladonna ML, et al. (2006) Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma. Cancer Res 66: 2630–2638. doi: 10.1158/0008-5472.CAN-05-1682
    [102] Kim SM, Lim JY, Park SI, et al. (2008) Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 68: 9614–9623. doi: 10.1158/0008-5472.CAN-08-0451
    [103] Ahmed AU, Rolle CE, Tyler MA, et al. (2010) Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model. Mol Ther 18: 1846–1856. doi: 10.1038/mt.2010.131
    [104] Herrlinger U, Woiciechowski C, Sena-Esteves M, et al. (2000) Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas. Mol Ther 1: 347–357. doi: 10.1006/mthe.2000.0046
    [105] Tyler MA, Ulasov IV, Sonabend AM, et al. (2009) Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther 16: 262–278. doi: 10.1038/gt.2008.165
    [106] Rigg A, Sikora K (1997) Genetic prodrug activation therapy. Mol Med Today 3: 359–366. doi: 10.1016/S1357-4310(97)01082-4
    [107] Kim JH, Kim JY, Kim SU, et al. (2012) Therapeutic effect of genetically modified human neural stem cells encoding cytosine deaminase on experimental glioma. Biochem Biophys Res Commun 417: 534–540. doi: 10.1016/j.bbrc.2011.11.155
    [108] Luo Y, Zhu D, Lam DH, et al. (2015) A Double-Switch Cell Fusion-Inducible Transgene Expression System for Neural Stem Cell-Based Antiglioma Gene Therapy. Stem Cells Int 2015: 649080.
    [109] Amano S, Li S, Gu C, et al. (2009) Use of genetically engineered bone marrow-derived mesenchymal stem cells for glioma gene therapy. Int J Oncol 35: 1265–1270.
    [110] Miletic H, Fischer YH, Litwak S, et al. (2007) Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene. Mol Ther 15: 1373–1381. doi: 10.1038/sj.mt.6300155
    [111] Lee EX, Lam DH, Wu C, et al. (2011) Glioma gene therapy using induced pluripotent stem cell derived neural stem cells. Mol Pharm 8: 1515–1524. doi: 10.1021/mp200127u
  • This article has been cited by:

    1. Samuel Rufat, Alexander Fekete, Iuliana Armaş, Thomas Hartmann, Christian Kuhlicke, Tim Prior, Thomas Thaler, Ben Wisner, Swimming alone? Why linking flood risk perception and behavior requires more than “it's the individual, stupid”, 2020, 7, 2049-1948, 10.1002/wat2.1462
    2. Alexander Fekete, Thomas Hartmann, Robert Jüpner, Resilience: On‐going wave or subsiding trend in flood risk research and practice?, 2020, 7, 2049-1948, 10.1002/wat2.1397
    3. Miranda PM Meuwissen, Mariska JM Bottema, Lien Hong Ho, Sawitree Chamsai, Kebede Manjur, Yann de Mey, The role of group-based contracts for risk-sharing; what are the opportunities to cover catastrophic risk?, 2019, 41, 18773435, 80, 10.1016/j.cosust.2019.11.004
    4. Mathilde Gralepois, What Can We Learn from Planning Instruments in Flood Prevention? Comparative Illustration to Highlight the Challenges of Governance in Europe, 2020, 12, 2073-4441, 1841, 10.3390/w12061841
    5. Jenia Gutman, 2019, Chapter 13, 978-3-030-23841-4, 127, 10.1007/978-3-030-23842-1_13
    6. M. Kaufmann, Limits to change - institutional dynamics of Dutch flood risk governance, 2018, 11, 1753318X, 250, 10.1111/jfr3.12307
    7. T. Busscher, M. van den Brink, S. Verweij, Strategies for integrating water management and spatial planning: Organising for spatial quality in the Dutch “Room for the River” program, 2019, 12, 1753318X, e12448, 10.1111/jfr3.12448
    8. Margo van den Brink, Jurian Edelenbos, Adri van den Brink, Stefan Verweij, Rudi van Etteger, Tim Busscher, To draw or to cross the line? The landscape architect as boundary spanner in Dutch river management, 2019, 186, 01692046, 13, 10.1016/j.landurbplan.2019.02.018
    9. Lukas Löschner, Ralf Nordbeck, Switzerland’s transition from flood defence to flood-adapted land use–A policy coordination perspective, 2020, 95, 02648377, 103873, 10.1016/j.landusepol.2019.02.032
    10. Lena Junger, Severin Hohensinner, Karin Schroll, Klaus Wagner, Walter Seher, Land Use in Flood-Prone Areas and Its Significance for Flood Risk Management—A Case Study of Alpine Regions in Austria, 2022, 11, 2073-445X, 392, 10.3390/land11030392
    11. Peter R. Davids, Sally Priest, Thomas Hartmann, On the horns of a dilemma: Experts as communicators for property‐level flood risk adaptation measures, 2023, 1753-318X, 10.1111/jfr3.12881
    12. Nuria Holguin, Arantza Mugica, Olatz Ukar, How Is Climate Change Included in the Implementation of the European Flood Directive? Analysis of the Methodological Approaches of Different Countries, 2021, 13, 2073-4441, 1490, 10.3390/w13111490
    13. Maria Kaufmann, Mark Wiering, The role of discourses in understanding institutional stability and change – an analysis of Dutch flood risk governance, 2022, 24, 1523-908X, 1, 10.1080/1523908X.2021.1935222
    14. Carla S. S. Ferreira, Zahra Kalantari, Thomas Hartmann, Paulo Pereira, 2021, Chapter 776, 978-3-030-77504-9, 1, 10.1007/698_2021_776
    15. Maoxin Zhang, Ge Zhai, Tingting He, Cifang Wu, A growing global threat: Long-term trends show cropland exposure to flooding on the rise, 2023, 899, 00489697, 165675, 10.1016/j.scitotenv.2023.165675
    16. Britta Restemeyer, Margo van den Brink, Jos Arts, A policy instruments palette for spatial quality: lessons from Dutch flood risk management, 2024, 1523-908X, 1, 10.1080/1523908X.2024.2328072
    17. Antoine Brochet, Jean-Dominique Creutin, Aida Arik, Yvan Renou, Towards hydrosocial autonomy within modernity. A long-term analysis (1850–1980) of socio-material fracturing of flood protection infrastructures in an Alpine valley, 2025, 116, 09626298, 103249, 10.1016/j.polgeo.2024.103249
  • Reader Comments
  • © 2018 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(5285) PDF downloads(1075) Cited by(2)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog